Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,040 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy.
Alig AHS, Heinemann V, Geissler M, Fischer von Weikersthal L, Decker T, Heinrich K, Held S, Weiss L, Fischer LE, Moosmann N, Stahler A, Jelas I, Kurreck A, von Einem JC, Reinacher-Schick AC, Tannapfel A, Giessen-Jung C, Stintzing S, Modest DP. Alig AHS, et al. Among authors: weiss l. Cancers (Basel). 2022 Jan 21;14(3):526. doi: 10.3390/cancers14030526. Cancers (Basel). 2022. PMID: 35158793 Free PMC article.
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Stahler A, Heinemann V, Holch JW, von Einem JC, Westphalen CB, Heinrich K, Schlieker L, Jelas I, Alig AHS, Fischer LE, Weiss L, Modest DP, von Weikersthal LF, Decker T, Kiani A, Moehler M, Kaiser F, Kirchner T, Jung A, Stintzing S. Stahler A, et al. Among authors: weiss l. Int J Cancer. 2021 Dec 1;149(11):1935-1943. doi: 10.1002/ijc.33747. Epub 2021 Jul 31. Int J Cancer. 2021. PMID: 34310714
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Fischer LE, Stintzing S, von Weikersthal LF, Modest DP, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Giessen-Jung C, Uhlig J, Peuser B, Denzlinger C, Stahler A, Weiss L, Heinrich K, Held S, Jung A, Kirchner T, Heinemann V. Fischer LE, et al. Among authors: weiss l. Br J Cancer. 2022 Sep;127(5):836-843. doi: 10.1038/s41416-022-01854-y. Epub 2022 May 30. Br J Cancer. 2022. PMID: 35637412 Free PMC article. Clinical Trial.
Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers.
Fischer LE, Stintzing S, Heinemann V, Keilholz U, Keune D, Vollbrecht C, Burmeister T, Kind A, Weiss L, Horst D, Kirchner T, Klauschen F, Jung A, Westphalen CB, Jelas I. Fischer LE, et al. Among authors: weiss l. Front Oncol. 2022 May 12;12:870411. doi: 10.3389/fonc.2022.870411. eCollection 2022. Front Oncol. 2022. PMID: 35646657 Free PMC article.
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.
Dorman K, Gerckens M, Kruger S, Krueger K, Mayer Z, Rupp A, Zhang D, Weiss L, Westphalen CB, Haas M, Guenther M, Ormanns S, Klawonn F, Werner J, von Bergwelt-Baildon M, Heinemann V, Boeck S, Holdenrieder S. Dorman K, et al. Among authors: weiss l. J Cancer Res Clin Oncol. 2023 Jun;149(6):2463-2474. doi: 10.1007/s00432-022-04112-z. Epub 2022 Jun 23. J Cancer Res Clin Oncol. 2023. PMID: 35737090 Free PMC article.
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.
Dorman K, Zhang D, Heinrich K, Reeh L, Weiss L, Haas M, Beyer G, Rössler D, Goni E, Renz BW, D'Haese JG, Kunz WG, Seidensticker M, Corradini S, Niyazi M, Ormanns S, Kumbrink J, Jung A, Klauschen F, Werner J, Mayerle J, von Bergwelt-Baildon M, Boeck S, Heinemann V, Westphalen CB. Dorman K, et al. Among authors: weiss l. Target Oncol. 2023 Mar;18(2):257-267. doi: 10.1007/s11523-023-00950-0. Epub 2023 Feb 28. Target Oncol. 2023. PMID: 36853374 Free PMC article.
A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich.
Zhang D, Dorman K, Heinrich K, Weiss L, Boukovala M, Haas M, Greif PA, Ziemann F, Beyer G, Roessler D, Goni E, Renz B, D'Haese JG, Kunz WG, Seidensticker M, Corradini S, Niyazi M, Ormanns S, Kumbrink J, Jung A, Mock A, Rudelius M, Klauschen F, Werner J, Mayerle J, von Bergwelt-Baildon M, Boeck S, Heinemann V, Westphalen CB. Zhang D, et al. Among authors: weiss l. Target Oncol. 2023 Sep;18(5):767-776. doi: 10.1007/s11523-023-00985-3. Epub 2023 Aug 18. Target Oncol. 2023. PMID: 37594677 Free PMC article.
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
Weiss L, Heinemann V, Fischer LE, Gieseler F, Hoehler T, Mayerle J, Quietzsch D, Reinacher-Schick A, Schenk M, Seipelt G, Siveke JT, Stahl M, Vehling-Kaiser U, Waldschmidt DT, Dorman K, Zhang D, Westphalen CB, von Bergwelt-Baildon M, Boeck S, Haas M. Weiss L, et al. Clin Transl Oncol. 2024 May;26(5):1268-1272. doi: 10.1007/s12094-023-03323-1. Epub 2023 Oct 4. Clin Transl Oncol. 2024. PMID: 37794220 Free PMC article.
Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
Zhang D, Benedikt Westphalen C, Quante M, Waldschmidt DT, Held S, Kütting F, Dorman K, Heinrich K, Weiss L, Boukovala M, Haas M, Boeck S, Heinemann V, Probst V. Zhang D, et al. Among authors: weiss l. Eur J Cancer. 2024 Apr;201:113926. doi: 10.1016/j.ejca.2024.113926. Epub 2024 Feb 15. Eur J Cancer. 2024. PMID: 38401449 Free article. Clinical Trial.
Treosulfan-Versus Melphalan-Based Reduced Intensity Conditioning in HLA-Haploidentical Transplantation for Patients ≥ 50 Years with Advanced MDS/AML.
Fraccaroli A, Stauffer E, Haebe S, Prevalsek D, Weiss L, Dorman K, Drolle H, von Bergwelt-Baildon M, Stemmler HJ, Herold T, Tischer J. Fraccaroli A, et al. Among authors: weiss l. Cancers (Basel). 2024 Aug 16;16(16):2859. doi: 10.3390/cancers16162859. Cancers (Basel). 2024. PMID: 39199629 Free PMC article.
3,040 results